Gengqian Cai

Statistics

Publications

Citations

441

H-Index

Active since

2005

Affiliations

GlaxoSmithKline (United States)(Current)

GlaxoSmithKline (United Kingdom)

King's College London

Cambridge University Hospitals NHS Foundation Trust

Temple University

Gengqian Cai is an author at GlaxoSmithKline (United States) specializing in pharmacology, clinical pharmacology, and p38 mitogen-activated protein kinase signaling.

Publications per year

2005–2019

Publications

Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial

L. Kristin Newby, Michael Marber, Chiara Melloni et al. · The Lancet · 2014 · 155 citations

Medicine, Cardiology, Pharmacology +14

Effects of p38 Mitogen-Activated Protein Kinase Inhibition on Vascular and Systemic Inflammation in Patients With Atherosclerosis

Maysoon Elkhawad, James H.F. Rudd, Lea Sarov‐Blat et al. · JACC. Cardiovascular imaging · 2012 · 153 citations

Veterinary Medicine, Pharmacology, Physiology +14

Effect of belimumab on proteinuria and anti-phospholipase A2 receptor autoantibody in primary membranous nephropathy

Christine Barrett, Lisa Willcocks, Rachel Jones et al. · Nephrology Dialysis Transplantation · 2019 · 71 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Safety, tolerability, pharmacokinetics and pharmacodynamics of losmapimod following a single intravenous or oral dose in healthy volunteers

April Barbour, Lea Sarov‐Blat, Gengqian Cai et al. · British Journal of Clinical Pharmacology · 2012 · 27 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +13

Predictive Models of Choroidal Neovascularization and Geographic Atrophy Incidence Applied to Clinical Trial Design

Linda McCarthy, Paul J. Newcombe, John C. Whittaker et al. · American Journal of Ophthalmology · 2012 · 13 citations

Medicine, Ophthalmology, Ocular Pathology +6

1–5 of 7